OREANDA-NEWS. According to the results of the first half of 2014 total sales of the top five best selling Rx drugs amounted to RUR 948.2 million, which corresponds to 48.5% of sales in the Rx drugs segment and 35.3%[1] of the Company's total sales.

According to the results of the first half of 2014 the top five best selling Rx drugs are:

Geptor (Ademetionine; ATC[2] "Digestive tract and metabolism"); 20.6% of sales in the Rx drugs segment;

Cerepro (Choline Alfoscerate; ATC "Medications for the treatment of the nervous system diseases"); sales in the segment made 10.2%;

Tautax (Docetaxel; ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 6.4%;

Irunine (Itraconazole; ATC "Antimicrobials for systematic use"); sales in the segment made 6.3%;

Amigrenin (Sumatriptan; ATC "Medications for the treatment of the nervous system diseases"); sales in the segment made 5.0%.

OTC drugs

OTC drugs segment is characterized by the high degree of consolidation. Total sales of the top five best selling OTC drugs amounted to RUR 398.3 million, which corresponds to 98.6% of sales in the OTC drugs segment and 14.8% of the Company's total sales.

According to the results of the first half of 2014 the top five best selling medicines are as follows:

Xilen (Xylometazoline; ATC "Medications for the treatment of respiratory system"); sales in the OTC drugs segment made 60.7%;

Slabilen (Sodium picosulfate; ATC "Alimentary tract and metabolism"); sales in the segment made 17.9%;

Motilak (Domperidone; ATC "Alimentary tract and metabolism"); sales in the OTC drugs segment made 17.9%;

Vitasharm and Vitatress (ATC "Vitamins"); sales in the segment made 1.2%;

Ginkgo biloba (Ginkgo biloba; ATC "Medications for the treatment of urogenital organs"); sales in the OTC drugs segment made 0.9%.

Non-pharamaceutical products

Total sales of the top five best selling non-pharmaceutical products amounted to RUR 314.5 million, which corresponds to 95.4% of sales in the segment and 11.7% of the Company's total sales.

According to the results of the first half of 2014 the top five best selling medicines are as follows:

Conventional antimicrobial adhesive bandages; 32.9% of sales in the segment;

Therapeutic patches - corn plasters; 26.4% of sales in the segment;

Conventional reel adhesive bandages; 19.5% of sales in the segment;

Therapeutic patches - pepper plasters; 13.0% of sales in the segment;

Comida (“Nutritional therapy”); 3.6% of sales in the segment.

NEW DRUGS PRODUCTION (including outsourcing) AND SALES

In the first half of 2014 Veropharm initiated production and sales of new forms and dosages of the following drugs:

Anfibra (Enoxaparin sodium; ATC "Medications affecting hematogenesis and blood") new form - syringes;

Bixikam (Meloxicam; Medications for the treatment of the musculoskeletal system) new dosage;

Gistamel (Imatinib; ATC "Antineoplastic and immunomodulating agents") new dosage;

Maverex (Vinorelbine, ATC "Antineoplastic and immunomodulating agents") new dosage;

Tautax (Docetaxel; ATC "Antineoplastic and immunomodulating agents"); new dosage;

Anti-bacterial napkins “Veropharm”;

Absorbing napkins “Asonia”;

“Nutrico Diet®” (dietary products for weight control).

NEW DRUGS REGISTRATION

In the first half of 2014 the following drugs have been registered in Russia;

ATC "Alimentary tract and metabolism"- 1 drug;

2 dietary supplements of foreign manufacture;

1 domestic cosmetic product;

1 substance is included in the State Register of Medicinal Remedies.

At present 68 products are in the development plan and 24 of them are currently at different stages of the registration process.

In the first half of 2014 the following drugs have been registered in CIS and Mongolia.

ATC "Antineoplastic agent" - 4 drugs;

ATC "Proteolysis inhibitor" - 1drug;

ATC "Immunomodulating agent" - 2 drug;

ATC "Alimentary tract and metabolism"- 1 drug.

At present 15 products are in the registration process.

[1] % - percent of finished goods sales

[2] ATC - anatomico-therapeutico-chemical group